Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
Authors
Keywords
-
Journal
ONCOGENE
Volume 36, Issue 46, Pages 6480-6489
Publisher
Springer Nature
Online
2017-07-31
DOI
10.1038/onc.2017.242
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation inApcΔ716mice involves stromal COX-2
- (2015) Teruaki Fujishita et al. CANCER SCIENCE
- HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer
- (2014) Si-Meng Chen et al. INTERNATIONAL JOURNAL OF CANCER
- Targeted Therapy for Breast Cancer
- (2013) Ali Mohamed et al. AMERICAN JOURNAL OF PATHOLOGY
- Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma
- (2013) Quan Wang et al. PLoS One
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)
- (2012) S. V. Holt et al. CANCER RESEARCH
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- The Behavior of Matrix Metalloproteinases and Their Inhibitors in Colorectal Cancer
- (2012) László Herszényi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models
- (2012) Hiroko Oshima et al. JOURNAL OF GASTROENTEROLOGY
- mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment
- (2011) Q. Jiang et al. CANCER RESEARCH
- JNK Signaling Promotes Intestinal Tumorigenesis Through Activation of mTOR Complex 1 in ApcΔ716 Mice
- (2011) Teruaki Fujishita et al. GASTROENTEROLOGY
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
- (2011) Y. Yu et al. SCIENCE
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Dvl2 Promotes Intestinal Length and Neoplasia in the ApcMin Mouse Model for Colorectal Cancer
- (2010) C. Metcalfe et al. CANCER RESEARCH
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in Apc 716 mice
- (2008) T. Fujishita et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started